|
|
|
| Curative Effect of Rabeprazole Combined with Droperitiazole Meretroxine in the Treatment of Patients with Chronic Atrophic Gastritis and its Effect on Serum sIL-2R MDA and G-17 |
| WANG Jian, CHEN Zhitao, ZHOU Tingting, et al |
| Wuhan Central Hospital, Hubei Wuhan 430000, China |
|
|
|
|
Abstract Objective: To observe the curative effect of rabeprazole combined with droperitiazole meretroxine in the treatment of patients with chronic atrophic gastritis and its effect on serum soluble interleukin-2 receptor (sIL -2R), malondialdehyde (MDA) and gastric secrete element-17 (G-17). Methods: 96 cases of chronic atrophic gastritis patients from December 2015 to December 2017, according to the simple random number table method these patients were divided into control group and research group,48 cases in each group. control group was treated with rabeprazole, and the research group was treated with flupipertiazol tablet united rabeprazole. Then curative effect, SF-36 scale score, anxiety, depression scores and symptom scores,sIL-2R,MDA,G-17, and adverse reactions occur between two group were and compared. Results: Total effective rate of the experimental group 95.83% was significantly higher than the control group 79.18% (P<0.05). Before treatment, SF-36 scale score, anxiety, depression scores and symptom scores,sIL-2R,MDA,G-17 of two group was no statistically significant (P>0.05). 2 weeks after treatment, 4 weeks after treatment, SF-36 scale score, G-17 of experimental group was significantly increased than after the treatment, the treatment group was significantly higher than the control group, anxiety depression scale and symptom scores, sIL-2R, MDA of two group was significantly reduced than after treatment, the experimental group was significantly lower than the control group,the difference was statistically significant (P<0.05). The adverse effects rate in both group was no statistical significance (P>0.05). Conclusion: curative effect of rabeprazole combined with droperitiazole meretroxine in the treatment of patients with chronic atrophic gastritis is sure, can significantly improve the clinical symptoms of patients,improve health,,it may be more conducive to regulating sIL-2R, MDA, and G-17 levels.
|
|
|
|
|
|
[1] 王仲略,周刚,沈慧琳.慢性萎缩性胃炎患者的危险因素与临床治疗效果[J].中华医院感染学杂志,2015,25(8):1817~1819.
[2] 周子力.萎缩性胃炎患者血清胃泌素族及血清、组织氧化应激指标的变化[J].海南医学院学报,2015,21(2):178~180.
[3] 康继厚,陈克河,曾静,等.雷贝拉唑治疗慢性萎缩性胃炎的临床疗效及其对血清胃泌素和内皮素水平的影响研究[J].中国全科医学,2017,20(s1):133~135.
[4] 朱姣,刘晶晶,代二庆.慢性萎缩性胃炎患者心理健康状况的相关性研究进展[J].辽宁中医杂志,2014,41(12):2714~2716.
[5] 胡楚胜,周坦峰,姜蕊,等.雷贝拉唑联合柴胡舒肝丸治疗老年慢性萎缩性胃炎疗效及对血清胃泌素和内皮素的影响[J].现代中西医结合杂志,2016,25(28):3162~3164.
[6] 李琼,刘晏,吴坚炯.慢性萎缩性胃炎的治疗进展[J].中医学报,2013,28(1):114~116.
[7] 张峰,王卫国,谢燕,等.抗抑郁治疗对慢性萎缩性胃炎伴抑郁患者炎症因子及生活质量的影响[J].山西医药杂志,2017,46(20):2461~2463.
[8] 关庆才,王邦茂.氟哌噻吨美利曲辛片辅助治疗功能性消化不良的Meta分析[J].中国医药,2014,9(1):77~80. |
|
|
|
2019, Vol. 25 
